No abstract

No abstract

Previous works on vehicle Re-ID mainly focus on extracting global features and learning distance metrics. Because some vehicles commonly share same model and maker, it is hard to distinguish them based on their global appearances. Compared with the global appearance, local regions such as decorations and inspection stickers attached to the windshield, may be more distinctive for vehicle Re-ID. To embed the detailed visual cues in those local regions, we propose a Region-Aware deep Model (RAM). Specifically, in addition to extracting global features, RAM also extracts features from a series of local regions. As each local region conveys more distinctive visual cues, RAM encourages the deep model to learn discriminative features. We also introduce a novel learning algorithm to jointly use vehicle IDs, types/models, and colors to train the RAM. This strategy fuses more cues for training and results in more discriminative global and regional features. We evaluate our methods on two large-scale vehicle Re-ID datasets, i.e., VeRi and VehicleID. Experimental results show our methods achieve promising performance in comparison with recent works.Index Terms-Vehicle Re-ID, Deep Convolutional Neural Network (DCNN), Region-Aware Deep Model

Maricite NaFePO 4 nanodots with minimized sizes (≈1.6 nm) uniformly embedded in porous N-doped carbon nanofibers (designated as NaFePO 4 @C) are first prepared by electrospinning for maximized Na-storage performance. The obtained flexible NaFePO 4 @C fiber membrane adherent on aluminum foil is directly used as binder-free cathode for sodium-ion batteries, revealing that the ultrasmall nanosize effect as well as a high-potential desodiation process can transform the generally perceived electrochemically inactive maricite NaFePO 4 into a highly active amorphous phase; meanwhile, remarkable electrochemical performance in terms of high reversible capacity (145 mA h g −1 at 0.2 C), high rate capability (61 mA h g −1 at 50 C), and unprecedentedly high cyclic stability (≈89% capacity retention over 6300 cycles) is achieved. Furthermore, the soft package Na-ion full battery constructed by the NaFePO 4 @C nanofibers cathode and the pure carbon nanofibers anode displays a promising energy density of 168.1 Wh kg −1 and a notable capacity retention of 87% after 200 cycles. The distinctive 3D network structure of very fine NaFePO 4 nanoparticles homogeneously encapsulated in interconnected porous N-doped carbon nanofibers, can effectively improve the active materials' utilization rate, facilitate the electrons/Na + ions transport, and strengthen the electrode stability upon prolonged cycling, leading to the fascinating Na-storage performance.

Purpose: Responses to therapy with chimeric antigen receptor T cells recognizing CD19 (CART19, CTL019) may vary by histology. Mantle cell lymphoma (MCL) represents a B-cell malignancy that remains incurable despite novel therapies such as the BTK inhibitor ibrutinib, and where data from CTL019 therapy are scant. Using MCL as a model, we sought to build upon the outcomes from CTL019 and from ibrutinib therapy by combining these in a rational manner.Experimental Design: MCL cell lines and primary MCL samples were combined with autologous or normal donor-derived anti-CD19 CAR T cells along with ibrutinib. The effect of the combination was studied in vitro and in mouse xenograft models.Results: MCL cells strongly activated multiple CTL019 effector functions, and MCL killing by CTL019 was further enhanced in the presence of ibrutinib. In a xenograft MCL model, we showed superior disease control in the CTL019-as compared with ibrutinib-treated mice (median survival not reached vs. 95 days, P < 0.005) but most mice receiving CTL019 monotherapy eventually relapsed. Therefore, we added ibrutinib to CTL019 and showed that 80% to 100% of mice in the CTL019 þ ibrutinib arm and 0% to 20% of mice in the CTL019 arm, respectively, remained in long-term remission (P < 0.05).Conclusions: Combining CTL019 with ibrutinib represents a rational way to incorporate two of the most recent therapies in MCL. Our findings pave the way to a two-pronged therapeutic strategy in patients with MCL and other types of B-cell lymphoma.